Giuliano Bedoschi

Dr. Giuliano Bedoschi


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2016 in Future Oncology
Verified
Journal Article
Closed access
GBGiuliano Bedoschi
Giuliano Bedoschi
PNPaula Andrea Navarro
Paula Andrea Navarro
KOKutluk Oktay
Kutluk Oktay
Cancer is a major public health problem around the world. Currently, about 5% of women diagnosed with cancer are of reproductive age. These young survivors may face compromised fertility. The effects of chemotherapeutic agents on ovarian reserve and its clinical consequences are generally inferred from a variety of surrogate markers of ovarian reserve, all aiming to provide prognostic information on fertility or the likelihood of success of infertility treatment. Until recently, the mechanisms that are responsible for chemotherapy-induced ovarian damage were not fully elucidated. The understanding of these mechanisms may lead to targeted treatments to preserve fertility. In this manuscript, we will review the current knowledge on the mechanism of ovarian damage and clinical impact of chemotherapy agents on fertility.

2 July 2018 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
Sandro EstevesSandro Esteves
Sandro Esteves
MRMatheus Roque
Matheus Roque
GBGiuliano Bedoschi
Giuliano Bedoschi
THThor Haahr
Thor Haahr
PHPeter Humaidan
Peter Humaidan

17 August 2018 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
Sandro EstevesSandro Esteves
Sandro Esteves
MRMatheus Roque
Matheus Roque
GBGiuliano Bedoschi
Giuliano Bedoschi
ACAlessandro Conforti
Alessandro Conforti
PHPeter Humaidan
Peter Humaidan
CACarlo Alviggi
Carlo Alviggi
Women with impaired ovarian reserve or poor ovarian response (POR) to exogenous gonadotropin stimulation present a challenge for reproductive specialists. The primary reasons relate to the still limited knowledge about the POR pathophysiology and the lack of practical solutions for the management of these conditions. Indeed, clinical trials using the current standards to define POR failed to show evidence in favor of a particular treatment modality. Furthermore, critical factors for reproductive success, such as the age-dependent embryo aneuploidy rates and the intrinsic ovarian resistance to gonadotropin stimulation, are not taken into consideration by the current POR criteria. As a result, the accepted definitions for POR have been criticized for their inadequacy concerning the proper patient characterization and for not providing clinicians a guide for therapeutic management. A novel system to classify infertility patients with “expected” or “unexpected” inappropriate ovarian response to exogenous gonadotropins—the POSEIDON criteria—was developed to provide a more nuanced picture of POR and to guide physicians in the management of such patients. The new standards are provoking as they challenge the current terminology of POR in favor of the newly defined concept of “low prognosis.” This article provides readers a critical appraisal of the existing criteria that standardize the definition of POR and explains the primary reasons for the development of the POSEIDON criteria.

1 May 2013 in Fertility and Sterility
Verified
Journal Article
Closed access
GBGiuliano Bedoschi
Giuliano Bedoschi
KOKutluk Oktay
Kutluk Oktay

1 January 2019 in Panminerva Medica
Verified
Journal Article
Closed access
GBGiuliano Bedoschi
Giuliano Bedoschi
PNPaula Andrea Navarro
Paula Andrea Navarro
KOKutluk H. Oktay
Kutluk H. Oktay
Cancer is the second leading cause of death in the USA and is considered a public health issue worldwide. Early diagnosis and advancement of treatment modalities contributed to declining mortality rates. Consequently, survival rates increased, leading to a greater interest in maintaining the quality of life after cancer treatment. Overall survival and disease-free survival rates are improved with the use of adjuvant chemotherapy. However, chemotherapy treatment might cause short and long-term side effects for cancer survivors. A special concern of young women diagnosed with cancer is their reproductive potential after chemotherapy. Chemotherapy drugs act by distinct mechanisms in the ovaries. DNA damage of primordial follicle oocytes, leading to chemotherapy-induced apoptosis, was recognized as the principal mechanism responsible for the irreversible decline of the ovarian reserve. The oocyte first attempts to repair DNA damage via the DNA damage repair pathway mediated by ataxia-telangiectasia mutated. Elimination through apoptosis occurs in cells in which DNA damage could not be repaired. In this review, the clinical impact and the major mechanisms of ovarian damage from chemotherapy treatment will be briefly described.

10 October 2013 in Current Breast Cancer Reports
Verified
Journal Article
Open access
PDF file
GBGiuliano Bedoschi
Giuliano Bedoschi
VTVolkan Turan
Volkan Turan
KOKutluk Oktay
Kutluk Oktay
Breast cancer is the most common type of malignancy in reproductive-age women. Breast cancer chemotherapy is associated with premature ovarian failure, infertility, and negative psychosocial effects related to these reproductive changes. As a result of this, fertility preservation becomes highly critical in this group of women. Besides the fertility preservation methods that utilize assisted reproductive technologies such as embryo, oocyte, and ovarian tissue cryopreservation, another suggested strategy for fertility preservation is suppression of ovarian ovulatory function by gonadotropin-releasing hormone agonist (GnRHa) administration before and during chemotherapy. However, both the efficacy and safety of GnRH agonists for prevention of ovarian damage are unproven and the preponderance of evidence indicates that this is an ineffective strategy. This review details the most recent information and studies on this controversial topic.